In continuation to our earlier intimation dated March 18, 2026, with respect to merger petition, we would like to inform that Hon''ble National Company Law Tribunal ("NCLT") on June 05, ....
M&A
▲ Positive Development
LOW RISK
📅 Filed on BSE: 05 Jun 2026, 05:29 PM IST · BSE ID: 5fa40006-e5e6-42c1-8291-d10e4b51d6bb
View Original BSE Filing (PDF)
💡
In Simple Terms
The court has approved the merger of Dhanuka Laboratories with Orchid Pharma, making it official.
🤖 AI Summary
- National Company Law Tribunal (NCLT), Chennai, sanctioned the Scheme of Amalgamation on June 05, 2026.
- The scheme involves Dhanuka Laboratories Limited (Amalgamating Company) with Orchid Pharma Limited (Amalgamated Company).
- Dhanuka Laboratories Limited will transfer to and vest in Orchid Pharma Limited on a going concern basis.
- This NCLT sanction is a continuation of the merger petition updates from March 18, 2026.
- Orchid Pharma Limited will submit the official NCLT order copy once it is made available.
🏢 How This Affects the Company
This sanction enables Orchid Pharma to integrate Dhanuka Laboratories' business operations and assets, potentially expanding its product portfolio or market reach.
The amalgamation will lead to a consolidation of financial statements, impacting Orchid Pharma's balance sheet, revenue, and profitability metrics going forward.
Orchid Pharma will commence the operational integration of Dhanuka Laboratories, which may involve consolidating manufacturing, supply chains, and administrative functions.
The completion of the NCLT approval reduces regulatory risk associated with the merger, shifting focus to integration execution risks.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this specific filing.
👤
Who Is Affected
Shareholders of Orchid Pharma Limited will now own a stake in the combined entity, which includes the assets and liabilities of Dhanuka Laboratories Limited.
🔍
Management Signal
Management is progressing with the strategic consolidation, demonstrating commitment to previously announced merger plans.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Receipt and submission of the official NCLT order copy by Orchid Pharma.
Disclosure of the effective date of the amalgamation scheme.
First consolidated financial results post-amalgamation for operational insights.
LOW RISK
The filing confirms a regulatory approval, reducing uncertainty related to the merger process.
💡 Investor Takeaway
The Hon'ble National Company Law Tribunal, Chennai, sanctioned the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited on June 05, 2026. This approval legally formalizes the merger, transferring Dhanuka Laboratories to Orchid Pharma on a going concern basis.
⚖️ Strengths & Concerns
✅ Positives
- NCLT sanction confirms the legal completion of the amalgamation process, removing regulatory uncertainty for the merger.
- The scheme transfers Dhanuka Laboratories to Orchid Pharma on a going concern basis, ensuring continuity of business operations.
📅 Company Track Record
Orchid Pharma had previously intimated about the merger petition on March 18, 2026, with this filing confirming the NCLT's sanction of the amalgamation scheme.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the key update regarding Orchid Pharma's merger with Dhanuka Laboratories?
The Hon'ble National Company Law Tribunal, Chennai, sanctioned the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited on June 05, 2026.
Which entity is the Amalgamating Company and which is the Amalgamated Company?
Dhanuka Laboratories Limited is the Amalgamating Company and Orchid Pharma Limited is the Amalgamated Company in this scheme of amalgamation.
What is the status of Dhanuka Laboratories Limited after the NCLT sanction?
Dhanuka Laboratories Limited will stand transferred to and vested in Orchid Pharma Limited on a going concern basis following the NCLT sanction on June 05, 2026.
When was the previous intimation regarding this merger petition by Orchid Pharma?
Orchid Pharma Limited previously provided an intimation regarding the merger petition on March 18, 2026.
Questions based on this BSE filing only. For information purposes.